ReviewContinuum (Minneapolis, Minn.)2012
Neurologic complications of HIV-1 infection and its treatment in the era of antiretroviral therapy.
Review in Continuum (Minneapolis, Minn.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- Guideline of the German Society of Neurology (DGN): "diagnosis and therapy of HIV-1-associated neurological disorders".Neurological research and practice · 2026Review
- Cognitive impairment is associated with poorer oral health in people with HIV: evidence from a pilot study.Quintessence international (Berlin, Germany : 1985) · 2026Article
- Review
- Psychiatric comorbidities in HIV/AIDS patients and its overlap with neurological disorders.Discover mental health · 2025Review
- Recent advances in nanotherapeutics for HIV-associated neurocognitive disorders and substance use disorders.Nanomedicine (London, England) · 2025Review
- Guillain-Barré syndrome: a comprehensive review.European journal of neurology · 2024Review
- Methamphetamine Enhancement of HIV-1 gp120-Mediated NLRP3 Inflammasome Activation and Resultant Proinflammatory Responses in Rat Microglial Cultures.International journal of molecular sciences · 2024Article
- Methamphetamine enhancement of HIV-1 gp120-mediated NLRP3 inflammasome activation and resultant proinflammatory responses in rat microglial cultures.Research square · 2023Article
- Prediction of incidence of neurological disorders in HIV-infected persons in Taiwan: a nested case-control study.BMC infectious diseases · 2023Article
- Occludin: a gatekeeper of brain Infection by HIV-1.Fluids and barriers of the CNS · 2023Review
- Selection of cognitive impairment screening tools for longitudinal implementation in an HIV clinical care setting.AIDS care · 2023Review
- Article
- Early-career research education mentoring: a successful program in NeuroHIV and mental health (TRNAMH).NeuroImmune pharmacology and therapeutics · 2023Article
- Neurological disorders in HIV: Hope despite challenges.Immunity, inflammation and disease · 2022Review
- HIV-1 Tat induced microglial EVs leads to neuronal synaptodendritic injury: microglia-neuron cross-talk in NeuroHIV.Extracellular vesicles and circulating nucleic acids · 2022Article
- Neuromuscular Complications of SARS-CoV-2 and Other Viral Infections.Frontiers in neurology · 2022Review
- Crucial Role of Central Nervous System as a Viral Anatomical Compartment for HIV-1 Infection.Microorganisms · 2021Review
- Humanized Mice for Infectious and Neurodegenerative disorders.Retrovirology · 2021Review
- Targeting Beclin1 as an Adjunctive Therapy against HIV Using Mannosylated Polyethylenimine Nanoparticles.Pharmaceutics · 2021Article
- The Causes and Long-Term Consequences of Viral Encephalitis.Frontiers in cellular neuroscience · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewNeurologic complications of HIV infection are unfortunately common, even in the era of effective antiretroviral treatment (ART). The consulting neurologist is often asked to distinguish among neurologic deterioration due to opportunistic infection (OI), immune reconstitution, or the effect of the virus itself, and to comment on the role of immunomodulatory agents in patients with HIV infection. Additionally, as successful virologic control has extended the life span of patients with HIV infection, neurologists are called upon to manage long-term complications, such as neurocognitive disorders and peripheral neuropathy. RECENT
findingsDespite the use of ART, significant numbers of patients continue to be affected by HIV-associated neurocognitive disorders, although with milder forms compared to the pre-ART era. Regimens of ART have been ranked according to CNS penetration and are being studied with regard to neuropsychological outcomes. Nucleoside analogs with the greatest potential for peripheral neurotoxicity are no longer considered first-line agents for HIV treatment. Efavirenz, a non-nucleoside reverse transcriptase inhibitor, has the greatest frequency of neurologic side effects among newer ART regimens. The spectrum of clinical manifestations of immune reconstitution inflammatory syndrome (IRIS) continues to grow, including IRIS without underlying OI. A greater understanding of pathophysiology and risk factors has shown that while HIV should be treated early to prevent severe immunocompromise, delayed initiation of ART may be helpful while treating OIs. SUMMARY: This article reviews the neurologic complications of HIV infection, or its treatment, most commonly encountered by neurologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.